Professor, Department of Pharmacy Practice & Science, College of Pharmacy, University of Arizona, Tucson, AZ. Email:
Am J Manag Care. 2018 Apr;24(7 Suppl):S107-S117.
In the United States, colon cancer is one of the leading causes of death and cancer-related death. There is a critical need to improve clinical outcomes in patients with metastatic colorectal cancer (mCRC), as current survival rates are unsatisfactory. There have been significant advances in the treatment of mCRC over the past decade. Molecular characteristics of mCRC and identification of mutations can serve predictive and prognostic indicators of disease response to treatment. These biomarkers can be incorporated into clinical decision making when developing an individualized treatment plan. Targeted therapies have improved the survival of patients with mCRC. As we learn about the various molecular alterations in this disease, additional emerging therapies can be developed to improve clinical outcomes in patients with mCRC.
在美国，结肠癌是导致死亡和癌症相关死亡的主要原因之一。改善转移性结直肠癌（mCRC）患者的临床结局至关重要，因为目前的生存率并不令人满意。在过去的十年中，mCRC 的治疗取得了重大进展。mCRC 的分子特征和突变的鉴定可以作为疾病对治疗反应的预测和预后指标。这些生物标志物可以在制定个体化治疗计划时纳入临床决策。靶向治疗改善了 mCRC 患者的生存率。随着我们对这种疾病的各种分子改变的了解，还可以开发出更多新的治疗方法，以改善 mCRC 患者的临床结果。
